SCHEMBL97521

SCHEMBL97521

O=Cc1ccc2ccscc1-2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.51
PTPRC P08575 1/20 0.36
CYP2A6 P11509 3/20 0.35
CYP2E1 P05181 2/20 0.35
CYP2B6 P20813 2/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
BACE1 P56817 1/20 0.35
PELI1 Q96FA3 1/20 0.35
KCNH2 Q12809 1/20 0.34
CYP17A1 P05093 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
XDH P47989 1/20 0.33
GSK3B P49841 1/20 0.33
ACMSD Q8TDX5 1/20 0.33
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
THRB P10828 1/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL97412 0.83 ERN1 (0.51) ERN1PTPRCCYP2A6CYP2E1CYP2B6
SCHEMBL609426 0.76 ERN1 (0.49) ERN1PTPRCCYP2A6CYP2E1CYP2B6
SCHEMBL21774240 0.76 ERN1 (0.49) ERN1PTPRCCYP2A6CYP2E1CYP2B6
SCHEMBL14919460 0.74 ERN1 (0.51) ERN1CYP2A6CYP2E1CYP2B6PELI1
SCHEMBL3718425 0.72 PTGS2 (0.50) ERN1ESR1ESR2MEN1LMNA
SCHEMBL15009485 0.72 ERN1 (0.76) ERN1PTPRCCYP2A6BACE1PELI1
SCHEMBL7998293 0.71 ERN1 (0.51) ERN1PELI1
SCHEMBL1244747 0.71 CYP2A6 (0.50) ERN1CYP2A6CYP2E1CYP2B6ESR1
SCHEMBL7525014 0.71 ERN1 (0.48) ERN1PTPRCCYP2A6CYP2E1CYP2B6
SCHEMBL16048725 0.68 MAPT (0.40) ERN1ESR1ESR2MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102190661-B Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD 2013-07-31 CN disclosed
US-8394974-B2 Process for producing optically active chromene oxide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-03-12 US disclosed
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
CN-1934116-B Tricyclic benzopyran compounds useful as antiarrhythmic agents NISSAN CHEMICAL IND LTD 2012-10-10 CN disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
CN-101437827-B Process for producing optically active chromene oxide compound NISSAN CHEMICAL IND LTD 2012-08-29 CN disclosed
CN-101429200-B Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD 2012-05-30 CN disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
CN-102190661-A Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD 2011-09-21 CN disclosed
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
EP-2003135-A2 PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND Nissan Chemical Industries, Ltd. (JP) 2008-12-17 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 US disclosed
CN-101068810-A Carbostyril compound OTSUKA PHARMA CO LTD (JP) 2007-11-07 CN disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
CN-1934116-A Tricyclic benzopyran compounds useful as antiarrhythmic agents NISSAN CHEMICAL IND LTD (JP) 2007-03-21 CN disclosed
EP-1732929-A1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS Nissan Chemical Industries, Ltd. (JP) 2006-12-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed
WO-2005090357-A1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 ERN1 3550/4885PTPRC 3063/4885CYP2A6 1200/4885
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents CBR1, CBR3, SCN8A ERN1 2050/4885PTPRC 3683/4885CYP2A6 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.